<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591328</url>
  </required_header>
  <id_info>
    <org_study_id>NCT1869</org_study_id>
    <nct_id>NCT03591328</nct_id>
  </id_info>
  <brief_title>Exploring the Mechanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and Computational Fluid Dynamics II (EMERALD II) Study</brief_title>
  <acronym>EMERALD II</acronym>
  <official_title>Exploring the Mechanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and Computational Fluid Dynamics II (EMERALD II) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea, Incheon St. Mary's hostpital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Semmelweis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ehime University Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gifu Heart Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EMERALD II study is a multinational, multicenter, and retrospective study. ACS patients
      who underwent CCTA from 2 months to 3 years prior to the event will be retrospectively
      identified. Plaques in the non-culprit vessels will be regarded as a primary control group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanisms of plaque rupture are not fully understood. Hemodynamic forces, plaque
      vulnerability, and the interaction between these factors may cause plaque instability and
      subsequent acute coronary syndrome (ACS). Previously, the first-in-human study, EMERALD I,
      showed that the addition of hemodynamic parameters calculated noninvasively from coronary
      computed tomography (CCTA) using computational fluid dynamics (CFD) improved the ability to
      predict the risk of acute coronary syndrome (ACS) compared with conventional approaches based
      on anatomical stenosis severity and adverse plaque characteristics. To validate the increment
      in discrimination and reclassification ability of a prediction model with hemodynamic
      parameters over a model with anatomical stenosis severity and adverse plaque characteristics.
      In this regard, we designed the subsequent EMERALD II study. In the EMERALD II study, we will
      refine methods for hemodynamic analysis and validate the previous algorithms on a much larger
      patient population. The study population will be divided into derivation and validation
      cohorts. Machine learning methods will be used to define a plaque rupture risk score based on
      plaque morphology, composition and hemodynamic forces in the derivation cohort, then the
      algorithm's prediction ability will be tested in the validation cohort.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>discrimination index of prediction model</measure>
    <time_frame>2 months - 3 years</time_frame>
    <description>discrimination index of prediction model</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1578</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Culprit</arm_group_label>
    <description>Plaques which is related with acute coronary syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-culprit</arm_group_label>
    <description>Plaques which is not related with acute coronary syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary CT angiography</intervention_name>
    <description>CCTA images will be screened for APC and CFD analyses. The presence of APC (low-attenuation plaque, positive remodeling, napkin-ring sign, and spotty calcification) will be assessed in each lesion by an independent observer blinded to the clinical data and CFD results according to the definitions from previous studies.
In order to evaluate incremental value of hemodynamic parameters, CFD will be performed in the independent core laboratory (HeartFlow Inc.). In consideration of potential clinical implications proposed in previous studies, 4 hemodynamic parameters will be computed for covariates in prediction models: 1) per-vessel FFR derived from cCTA (FFRCT); 2) change in FFRCT across the lesion (â–³FFRCT); 3) wall shear stress (WSS); and 4) axial plaque stress.</description>
    <arm_group_label>Culprit</arm_group_label>
    <arm_group_label>Non-culprit</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who presented with acute coronary syndrome (acute myocardial infarction or
        unstable angina) and had undergone CCTA from 2 months to 3 years prior to the event.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who presented with ACS and underwent invasive coronary angiography with
             identifiable culprit lesion

          2. The patients who underwent coronary CT angiography, regardless of the reason (for
             example, routine healthcare check-up, or evaluation for stable angina or atypical
             chest pain) prior to the acute event.

          3. Time limit of CCTA: 2 months ~ 3 years prior to the event.

          4. Definition of ACS:

        A. The patients with acute myocardial infarction should meet one of the following criteria;
        i. Cardiac enzyme elevation &quot;and&quot; ii. Identified culprit lesion confirmed by invasive
        coronary angiography, IVUS, or OCT B. The patients with unstable angina should be
        accompanied by the evidence of plaque rupture confirmed with invasive coronary angiography,
        IVUS, or OCT

        Exclusion Criteria:

          1. Exclusion criteria for Patient enrollment A. Patients with acute myocardial infarction
             without clear evidence of culprit lesion B. Secondary myocardial infarction due to
             other general medical conditions, such as sepsis, arrhythmia, bleeding, etc.

             C. Patients with unstable angina without evidence of plaque rupture D. Poor quality of
             CCTA which is unsuitable for plaque and CFD analysis E. Patients with previous history
             of coronary artery bypass graft surgery F. Patients with stents in two or more vessel
             territories prior to CCTA G. Patients with ACS culprit lesion in a stented vessel H.
             Patients with revascularization after CCTA and before ACS event

          2. Additional exclusion criteria for Computational Fluid Dynamics A. Reference vessel
             diameter &lt; 2.5mm on CCTA B. Poor quality CCTA images unsuitable for CFD analysis C. No
             available unprocessed CCTA data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bon-Kwon Koo, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joo Myung Lee, MD, MPH, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>July 8, 2018</last_update_submitted>
  <last_update_submitted_qc>July 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Bon-Kwon Koo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Unstable angina</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>Computational fluid dynamics</keyword>
  <keyword>Coronary computed tomography angiography</keyword>
  <keyword>Fractional flow reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

